JPH0468319B2 - - Google Patents

Info

Publication number
JPH0468319B2
JPH0468319B2 JP60108427A JP10842785A JPH0468319B2 JP H0468319 B2 JPH0468319 B2 JP H0468319B2 JP 60108427 A JP60108427 A JP 60108427A JP 10842785 A JP10842785 A JP 10842785A JP H0468319 B2 JPH0468319 B2 JP H0468319B2
Authority
JP
Japan
Prior art keywords
antibiotic
spectrum
culture
medium
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60108427A
Other languages
Japanese (ja)
Other versions
JPS61268187A (en
Inventor
Satoshi Oomura
Yuzuru Iwai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato Institute
Original Assignee
Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Institute filed Critical Kitasato Institute
Priority to JP60108427A priority Critical patent/JPS61268187A/en
Publication of JPS61268187A publication Critical patent/JPS61268187A/en
Publication of JPH0468319B2 publication Critical patent/JPH0468319B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

(産業上の利用分野) 本発明は、新規な抗生物質SK−1071およびそ
の製造法に関するものである。 (発明の構成) 本発明者らは、放線菌の生産する抗生物質の探
索の過程において、新たに土壌より分離した一放
線菌SK−1071が嫌気性細菌などに有効な新規抗
生物質を生産することを見い出した。本生産菌株
の同定および本物質を単離した後、理化学的およ
び生物学的性質を調べることにより本発明を完成
した。 本発明に係る構成物質SK−1071の理化学的性
状は、次のとおりである。 (1) 元素分析:C60.50% H6.07% (2) 分子量:630、高分解能マススペクトルでの
分子イオンピーク、m/z630、2315、元素分析
およびC−13核磁気共嗚スペクトル(第4図)
から分子式C32H33O13が求められる。 (3) 融点:130−233℃ (4) 比旋光度:〔α〕18 D−0.1゜(C=1、アセトニ

リル) (5) 紫外線吸収スペクトル:50%アセトニトリル
水溶液中で277nmおよび350nmに吸収極大を示
し、分子吸光係数はそれぞれ6170、4660(第1
図)。 (6) 赤外線吸収スペクトル:第2図のとおりであ
る。(KBr法) (7) プロトン核磁気共嗚スペクトル:第3図のと
おりである。 (8) C−13核磁気共嗚スペクトル:第4図のとお
りである。 (9) 溶剤に対する溶解性は、アセトニトリル、ア
セトン、酢酸エチルに可溶であり、水、n−ヘ
キサンに不溶である。 (10) 呈色反応は、過マンガン酸カリ、H2SO4
陽性、ドラーゲンドルフ、ニンヒドリンに陰性
である。 (11) 酸性物質である。 上記の理化学的性質および後述する生物活性を
有する点で、既知の抗生物質は存在しないので、
本発明による新規抗生物質をSK−1071と命名し
た。 本物質の生物学的性質は、次のとおりである。 (1) 抗菌性 寒天希釈法による最小阻止濃度(MIC)は、
第1表に示すとおりである。
(Industrial Application Field) The present invention relates to a novel antibiotic SK-1071 and a method for producing the same. (Structure of the Invention) In the process of searching for antibiotics produced by actinomycetes, the present inventors discovered that actinomycetes SK-1071, which was newly isolated from soil, produced a new antibiotic effective against anaerobic bacteria. I discovered that. After identifying the production strain and isolating the substance, the present invention was completed by investigating its physicochemical and biological properties. The physical and chemical properties of the constituent material SK-1071 according to the present invention are as follows. (1) Elemental analysis: C60.50% H6.07% (2) Molecular weight: 630, molecular ion peak in high-resolution mass spectrum, m/z 630, 2315, elemental analysis and C-13 nuclear magnetic resonance spectrum (second Figure 4)
The molecular formula C 32 H 33 O 13 can be found from (3) Melting point: 130-233℃ (4) Specific rotation: [α] 18 D -0.1゜ (C=1, acetonitrile) (5) Ultraviolet absorption spectrum: Maximum absorption at 277nm and 350nm in 50% acetonitrile aqueous solution The molecular extinction coefficients are 6170 and 4660 (first
figure). (6) Infrared absorption spectrum: As shown in Figure 2. (KBr method) (7) Proton nuclear magnetic resonance spectrum: As shown in Figure 3. (8) C-13 nuclear magnetic resonance spectrum: As shown in Figure 4. (9) Solubility in solvents: soluble in acetonitrile, acetone, and ethyl acetate, and insoluble in water and n-hexane. (10) Color reaction is positive for potassium permanganate and H 2 SO 4 and negative for Dragendorff and ninhydrin. (11) It is an acidic substance. Since there are no known antibiotics that have the above-mentioned physicochemical properties and the biological activities described below,
The novel antibiotic according to the present invention was named SK-1071. The biological properties of this substance are as follows. (1) Antibacterial properties The minimum inhibitory concentration (MIC) determined by the agar dilution method is
As shown in Table 1.

【表】 (2) 毒性 本抗生物質をマウス腹腔内投与した場合の
LD59は100mg/Kg以上である。 本発明の抗生物質SK−1071を生産するために
使用される微生物の実用的な例は、本発明者によ
つて土壌から分離された放線菌SK−1071株があ
げられる。この菌は、工業技術院微生物工業技術
研究所に受託番号「微工研菌寄第8107号」として
寄託されている。その菌学的性状は、次のとおり
である。 () 形態的性状 SK−1071株の栄養菌糸は、各種寒天培地でよ
く発達し、通常は隔壁を有しない。気菌糸は各種
寒天培地で豊富に着先し、ビロード状あるいは粉
状を呈する。顕微鏡下の観察では、気菌糸は螺旋
状を呈し、20ケ以上の胞子による長い連鎖を形成
する。胞子は円筒形で、表面は毛状である。胞子
の大きさは1.2×0.7μmである。菌核、胞子のうお
よび遊走子は観察されない。 () 各種培地上での培養性状 イ−・ビー・シヤーリング(E.B.Shirling)お
よびデイー・ゴツトリーブ(D.Gottlieb)の方法
〔インターナシヨナル・ジヤーナル・オブ・シス
テイマテツク・バクテリオロジ−(Int.J.Syst,
Bacteriol.)16,313(1966)〕によつて調べた本
生産菌の培養性状を次表に示す。色調は標準色と
して、カラー・ハーモニー・マニユアル(Color
Harmony Manual)第4版〔コンテナー・コー
ポレーシヨン・オブ・アメリカ(Container
Corporation of America)1958年〕を用いて決
定し、色票名とともに括弧内にそのコードを併せ
て記した。以下は特記しない限り、27℃、2週間
目の各培地における観察の結果である。
[Table] (2) Toxicity When this antibiotic was administered intraperitoneally to mice,
LD 59 is 100 mg/Kg or more. A practical example of the microorganism used to produce the antibiotic SK-1071 of the present invention is the actinomycete strain SK-1071, which was isolated from soil by the present inventor. This bacterium has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology under the accession number ``Feikoken Bacteria No. 8107''. Its mycological properties are as follows. () Morphological characteristics The vegetative hyphae of strain SK-1071 develop well on various agar media and usually do not have septa. Aerial mycelium is abundant on various agar media and appears velvety or powdery. When observed under a microscope, aerial hyphae appear spiral-shaped and form long chains of 20 or more spores. The spores are cylindrical and have a hair-like surface. The size of the spores is 1.2 x 0.7 μm. No sclerotia, sporangia and zoospores are observed. () Culture properties on various media Methods of EBShirling and D. Gottlieb [International Journal of Systematic Bacteriology (Int.J.Syst,
Bacteriol.) 16 , 313 (1966)], the culture properties of this producing bacterium are shown in the following table. The color tone is the standard color, and the Color Harmony Manual (Color
Harmony Manual) 4th Edition [Container Corporation of America
Corporation of America) in 1958], and the code is written in parentheses along with the color chart name. The following are the results of observations on each culture medium at 27°C for 2 weeks unless otherwise specified.

【表】【table】

【表】【table】

【表】 選定の培地
() 生理学的諸性質 (1) メラニン色素の生成 (イ) チロシンン寒天 陰性 (ロ) ペプトン・イースト鉄寒天 陰性 (ハ) グルコース・ベプトン・ゼラチン培地 (穿刺(21〜23℃) 陰性 (ニ) トリプトン・イースト液 陰性 (2) チロシナーゼ反応 陰性 (3) 硫化水素の生産 陰性 (4) 硝酸塩の還元 陽性 (5) ゼラチンの液化(21〜23℃) (グルコース・ペプトン・ゼラチン培地)陰性 (6) スターチの加水分解 陽性 (7) 脱脂乳の凝固(37℃) 陰性 (8) 脱脂乳のペプトン化(37℃) 陽性 (9) 生育温度範囲 15〜45℃ (10) 炭素源の利用性 (プリーダム・コドリーブ寒天培地) 利用する:D−グリコース、L−アラビノー
ス、D−キシロース、ラフイノース、メ
リビオース、D−マンニトール、D−フ
ルクトース、L−ラムノース、i−イノ
シトール、シユークロース (11) セルロースの分解 陰性 () 細胞の化学成分 ジアミノピメリン酸はLL型であり、全菌体の
糖の分析ではアラビノースとガラクトースが認ら
れた。 以上、本菌の菌学的性状を要約すると、次のと
おりになる。 細胞壁組成としてLL−ジアミノピメリン酸を
有する。また、形態的には、螺旋状の胞子鎖を形
成し、胞子の表面は毛状である。培養上の諸性質
としては、栄養菌糸はバンプーあるいはライトア
イボリーの色調を呈し、気菌糸はプラウニツシユ
グレイの色調を呈する。可溶性色素は生産しな
い。 これらの結果から、本菌はStreptomyces属に
属し、テイー・ジー・プリドハム(T.G.
Pridham)とエイチ・デー・トレスナー(H.D.
Tresner)の分類〔バージエーズ・マニユアル・
オブ・デタミネーテイブ・バクテリオロジイ
(Bergey′sManual of Determinative
Bacteriology)第8版,748〜829頁,1974年〕
によるグレイシリーズに属する菌種と考えられ
る。 上記菌株の変異株も本発明の方法に使用するこ
とができる。 培地としては、放線菌の培養に適する炭素源、
窒素源、無機物、必要に応じてその他の栄養物を
ほどよく含有する合成培地または天然培地を使用
することができる。 培地に使用される炭素源、窒素源は、使用菌株
の利用可能なものならばいずれの種類でもよい。
すなわち、炭素源としては、たとえば、グルコー
ス、グリセロール、フラクトース、マルトース、
マンニツト、キシロース、ガラクトース、リボー
ス、澱粉またはその加水分解物等の種々の炭水化
物が使用できる。その濃度は通常、培地に対して
0.1〜5%(グルコース換算)が好ましい。また、
グルコン酸、ピルビン酸、乳酸、酢酸等の各種有
機酸、グリシン、グルタミン酸、アラニン等の各
種アミノ酸、さらにはメタノール、エタノール等
のアルコール類や、ノルマルパラフイン等の各種
の非芳香族系炭化水素、あるいは植物性もしくは
動物性の各種油脂等も使用可能である。窒素源と
しては、アンモニア、塩化アンモニウム、燐酸ア
ンモニウム、硫酸アンモニウム、硝酸アンモニウ
ム等の各種の無機酸あるいは有機酸のアンモニウ
ム塩類、尿素、ペプトン、NZ−アミン、肉エキ
ス、酵母エキス、乾燥酵母、コーンスチープリカ
ー、カゼイン加水分解物、フイツシユミールある
いはその消化物、大豆粉あるいはその消化物、脱
脂大豆あるいはその消化物、蛹加水分解物等の含
窒素有機物質、さらにはグリシン、グルタミン
酸、アラニン等の各種アミノ酸が使用可能であ
る。 無機物としては各種燐酸塩、硫酸マグネシウ
ム、食塩等、さらに微量の重金属塩が使用され
る。 また、栄養要求性を示す変異株を用いる場合に
は、当然その栄養要求を満足させる物質を培地に
加えなければならないが、この種の栄養素は、天
然物を含む培地を使用する場合には、とくに添加
を必要としない場合がある。 発酵は振盪培養または通気撹拌深部培養等の好
気的条件下で行なう。培養温度は通常20〜40℃で
ある。培養期間は通常1〜8日で、菌体内外に抗
生物質SK−1071が生成蓄積する。 培養終了後に培養物より抗生物質SK−1071を、
たとえば、次の方法で採取する。培養物を遠心分
離により、液と沈澱物とに分離する。液から
は活性炭、多孔性合成高分子樹脂、イオン交換樹
脂等に吸着させ、溶出させることにより抽出す
る。沈澱物からは酢酸エチルまたはノルマルブタ
ノールや含水アセトン等の有機溶媒で抽出する。
抽出物を適宜濃縮乾固することにより、SK−
1071の粗物質を得る。粗物質はさらに、脂溶性物
質の精製において通常用いられる公知の方法、た
とえば、シリカゲルカラムクロマトグラフイー等
の濃縮法などを適宜組合わせることにより精製さ
れる。これらの精製方法で得られる活性画分を濃
縮乾固することにより、抗生物質SK−1071の粉
末を得ることができる。 本発明において、抗生物質SK−1071の検出お
よび定量は、シリカゲル薄層クロマトグラフイー
(メルク社製シリカゲル60F254、厚さ0.2nm、展
開溶媒ベンゼン/アセトン=3:1、抗生物質
SK−1071のRf値0.40)およびクロストリジウ
ム・パーフリンゲンス(Clostridium perfri−
ngens)ATCC3624を用いる生物学的検定法によ
つた。 (発明の効果) 上記のとおり抗生物質SK−1071は毒性が低く、
主として嫌気性細菌に活性を示す。したがつて、
本物質は、ヒトおよび動物の微生物感染症に対す
る治療薬、予防薬としての使用が期待される。 (実施例) 次に、本発明の抗生物質SK−1071の実施例を
示すが、この実施例は単なる一例を示すものであ
つて、本発明を限定するものではない。 放線菌SK−1071株(微工研寄第8107号)の斜
面培養から一白金耳を100mlの種培地(グルコー
ス0.1%、スターチ2.4%、ペプトン0.3%、肉エキ
ス0.3%、酵母エキス0.5%、炭酸カルシウム0.4
%)を入れた500ml容の坂口フラスコに接種し、
27℃で2日間振盪培養して種培養を得た。こ種培
養400mlを、40の生産培地(グルコース0.1%、
スターチ2.4%、ペプトン0.3%、肉エキス0.3%、
酵母エキス0.5%、炭酸カルシウム0.4%、硫酸第
一鉄7水塩1mg/、塩化マンガン4水塩1mg/
、硫酸亜鉛7水塩1mg/、硫酸銅5水塩1
mg/、塩化コバルト2水塩1mg/を入れた30
容ジヤーフアメンター2基に分けて接種し、27
℃で3日間通気撹拌培養(通気量10/mm、撹拌
250rpm)を行なつた。 培養液40をシヤープレス型遠心分離機を用い
て遠心分離し、菌体と培養上清に分離する。菌体
に90%アセトン溶液2.5を加え撹拌し、再抽出
を行なつた。 このアセトン溶液を減圧下で濃縮し、アセトン
を除去した後、培養上清18と合わせ、塩酸でPH
4に調整した。これを650mlのダイカイオンHp−
20を充填したカラムに通した後、70%アセトン水
で溶出し、1ずつ分画した。活性画分(No.1〜
3)を集めて減圧下濃縮し、アセトンを除去した
後、塩酸でPH3に調整し、1の酢酸エチルで回
抽出した。抽出液を減圧下で濃縮乾固することに
より、タール状物質840mgを得た。 タール状物質840mgをメタノールに溶解しセラ
イトと混合した後、濃縮乾固した。この粉末を3
mlベンゼンに懸濁し、あらかじめベンゼンに懸濁
させたシリカゲル(40g、メルク社製,
Art.9385)を充填したカラム上端に添加した。カ
ラムをベンゼン/アセトン(4:1)で溶出し、
10mlずつ分画した。活性画分(No.23〜39)を集め
て減圧下で濃縮することにより、油状物質150mg
を得た。 油状物質150mgは1.5mlアセトニトリルに溶か
し、15回に分けて高速液体クロマトグラフイー
(カラム、山村化学研究所製YMC A−324;展開
溶媒65%アセトニトリル水,流速3ml/mi,検
出 UV210nm;保持時間9.8分)を行なつた。こ
の活性分画を減圧下で濃縮乾固することにより、
白色粉末39mgを単離した。
[Table] Selected culture medium
() Physiological properties (1) Production of melanin pigment (a) Tyrosine agar negative (b) Peptone/yeast iron agar negative (c) Glucose/beptone/gelatin medium (puncture (21-23℃) negative (d) Tryptone・Yeast liquid negative (2) Tyrosinase reaction negative (3) Hydrogen sulfide production negative (4) Nitrate reduction positive (5) Liquefaction of gelatin (21-23℃) (Glucose/peptone/gelatin medium) Negative (6) Starch Hydrolysis of skim milk Positive (7) Coagulation of skim milk (37℃) Negative (8) Peptonization of skim milk (37℃) Positive (9) Growth temperature range 15-45℃ (10) Availability of carbon source (Pleadam Codolive agar medium) Used: D-glycose, L-arabinose, D-xylose, raffinose, melibiose, D-mannitol, D-fructose, L-rhamnose, i-inositol, sucrose (11) Degradation of cellulose Negative () cells The chemical composition of diaminopimelic acid is the LL type, and arabinose and galactose were found in the sugar analysis of the whole bacterial cell.The mycological properties of this bacterium can be summarized as follows.The cell wall composition is LL. - Contains diaminopimelic acid. Morphologically, it forms a spiral spore chain, and the surface of the spore is hair-like. As for its cultural properties, the vegetative hyphae exhibit a bumpy or light ivory color. , the aerial mycelium exhibits a brownish gray color. It does not produce soluble pigments. Based on these results, this fungus belongs to the genus Streptomyces, and T.G. Pridham (TG
Pridham) and H.D. Tresner (HD
Tresner) classification [Bergeys Manual
Bergey's Manual of Determinative Bacteriology
Bacteriology) 8th edition, pages 748-829, 1974]
It is considered to be a bacterial species belonging to the Gray series. Mutant strains of the above-mentioned strains can also be used in the method of the invention. As a medium, a carbon source suitable for culturing actinomycetes,
Synthetic or natural media containing moderate amounts of nitrogen sources, minerals, and optionally other nutrients can be used. The carbon source and nitrogen source used in the culture medium may be any type as long as they are available to the strain used.
That is, carbon sources include, for example, glucose, glycerol, fructose, maltose,
Various carbohydrates can be used, such as mannite, xylose, galactose, ribose, starch or its hydrolysates. Its concentration is usually
0.1 to 5% (calculated as glucose) is preferable. Also,
Various organic acids such as gluconic acid, pyruvic acid, lactic acid, and acetic acid, various amino acids such as glycine, glutamic acid, and alanine, alcohols such as methanol and ethanol, and various non-aromatic hydrocarbons such as normal paraffin, Various vegetable or animal fats and oils can also be used. Nitrogen sources include ammonium salts of various inorganic or organic acids such as ammonia, ammonium chloride, ammonium phosphate, ammonium sulfate, ammonium nitrate, urea, peptone, NZ-amine, meat extract, yeast extract, dried yeast, corn steep liquor, Nitrogen-containing organic substances such as casein hydrolyzate, fat meal or its digested product, soybean flour or its digested product, defatted soybean or its digested product, pupa hydrolysate, and various amino acids such as glycine, glutamic acid, and alanine can be used. It is. As inorganic substances, various phosphates, magnesium sulfate, common salt, etc., and trace amounts of heavy metal salts are used. Furthermore, when using a mutant strain that exhibits auxotrophy, it is of course necessary to add a substance to the medium that satisfies its nutritional requirements; however, when using a medium containing natural substances, There are cases where no particular addition is required. Fermentation is carried out under aerobic conditions such as shaking culture or submerged culture with aeration and stirring. The culture temperature is usually 20-40°C. The culture period is usually 1 to 8 days, and the antibiotic SK-1071 is produced and accumulated inside and outside the bacterial cells. After culturing, antibiotic SK-1071 was added to the culture.
For example, collect it using the following method. The culture is separated into a liquid and a precipitate by centrifugation. It is extracted from the liquid by adsorbing it onto activated carbon, porous synthetic polymer resin, ion exchange resin, etc. and eluting it. The precipitate is extracted with an organic solvent such as ethyl acetate, n-butanol, or aqueous acetone.
By appropriately concentrating the extract to dryness, SK-
1071 crude material is obtained. The crude substance is further purified by appropriately combining known methods commonly used in the purification of fat-soluble substances, such as concentration methods such as silica gel column chromatography. By concentrating and drying the active fraction obtained by these purification methods, powder of antibiotic SK-1071 can be obtained. In the present invention, the antibiotic SK-1071 was detected and quantified using silica gel thin layer chromatography (Silica gel 60F 254 manufactured by Merck & Co., Ltd., thickness 0.2 nm, developing solvent benzene/acetone = 3:1, antibiotic
SK-1071 Rf value 0.40) and Clostridium perfringens (Clostridium perfringens)
A biological assay using ATCC 3624 was used. (Effect of the invention) As mentioned above, antibiotic SK-1071 has low toxicity;
Mainly active against anaerobic bacteria. Therefore,
This substance is expected to be used as a therapeutic or preventive agent for microbial infections in humans and animals. (Example) Next, an example of the antibiotic SK-1071 of the present invention will be shown, but this example is merely an example and does not limit the present invention. A platinum loop from a slant culture of Actinomycetes strain SK-1071 (Feikoken No. 8107) was added to 100 ml of seed medium (glucose 0.1%, starch 2.4%, peptone 0.3%, meat extract 0.3%, yeast extract 0.5%, Calcium carbonate 0.4
%) into a 500 ml Sakaguchi flask,
A seed culture was obtained by culturing with shaking at 27°C for 2 days. Add 400ml of this seed culture to 40ml of production medium (glucose 0.1%,
Starch 2.4%, peptone 0.3%, meat extract 0.3%,
Yeast extract 0.5%, calcium carbonate 0.4%, ferrous sulfate heptahydrate 1mg/, manganese chloride tetrahydrate 1mg/
, zinc sulfate heptahydrate 1 mg/, copper sulfate pentahydrate 1
mg/, cobalt chloride dihydrate 1 mg/30
The vaccine was divided into two separate units and 27
Culture with aeration at ℃ for 3 days (aeration rate 10/mm, stirring
250rpm). The culture solution 40 is centrifuged using a shear press type centrifuge to separate the bacterial cells and the culture supernatant. 2.5 g of 90% acetone solution was added to the bacterial cells and stirred to perform re-extraction. After concentrating this acetone solution under reduced pressure to remove acetone, it was combined with culture supernatant 18, and the pH was adjusted with hydrochloric acid.
Adjusted to 4. Add this to 650ml of Daikaiion Hp−
After passing through a column packed with 20% acetone, it was eluted with 70% acetone water and fractionated into individual fractions. Active fraction (No. 1~
3) was collected and concentrated under reduced pressure to remove acetone, the pH was adjusted to 3 with hydrochloric acid, and the mixture was extracted twice with ethyl acetate. The extract was concentrated to dryness under reduced pressure to obtain 840 mg of a tar-like substance. 840 mg of tar-like substance was dissolved in methanol, mixed with Celite, and then concentrated to dryness. This powder is 3
Silica gel (40 g, manufactured by Merck, pre-suspended in benzene)
Art.9385) was added to the top of the column packed. The column was eluted with benzene/acetone (4:1);
It was fractionated into 10 ml portions. By collecting the active fractions (No. 23-39) and concentrating under reduced pressure, 150 mg of oily substance was obtained.
I got it. 150 mg of the oily substance was dissolved in 1.5 ml acetonitrile, and divided into 15 times, high performance liquid chromatography (column, YMC A-324 manufactured by Yamamura Kagaku Kenkyusho; developing solvent 65% acetonitrile water, flow rate 3 ml/mi, detection UV 210 nm; retention time 9.8 minutes). By concentrating this active fraction to dryness under reduced pressure,
39 mg of white powder was isolated.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図は抗生物質SK−1071の紫外線吸収スペ
クトル(50%アセトニトリル水溶液中の測定)、
第2図は赤外線吸収スペクトル(KBr法)、第3
図はプロトン核磁気共嗚スペクトル(重クロロホ
ルム中で測定)、第4図はC−13核磁気共嗚スペ
クトル(重アセトン中で測定)を示す。
Figure 1 shows the ultraviolet absorption spectrum of antibiotic SK-1071 (measured in 50% acetonitrile aqueous solution).
Figure 2 is an infrared absorption spectrum (KBr method), Figure 3 is
The figure shows the proton nuclear magnetic resonance spectrum (measured in deuterated chloroform), and FIG. 4 shows the C-13 nuclear magnetic resonance spectrum (measured in deuterated acetone).

Claims (1)

【特許請求の範囲】 1 次の理化学的性質を有し、分子式C32H38O13
で表される抗生物質SK−1071。 比旋光度:〔α〕18 D−0.1゜(C=1、アセトニト
リル) 紫外線吸収スペクトル:λCH 3 CN naxnm(ε)277
(6170)、350(4660)に吸収帯を有する。 赤外線吸収スペクトル:3400,1760,1740,
1710,1640,1600cm-1に吸収帯を有する。 C−13核磁気共嗚スペクトル:重アセトン中
のケミカルシフト ppm172.3(s),157.5
(d),144.0(s),139.5(s),135.3(s),
131.6(d),125.7(d),123.4(d),98.4(d)

88.9(d),79.5(d),76.8(s),74.3(d),73
.6
(t),69.7(d),67.4(d),66.3(d),63.3
(t),61.0(q),59.6(q),46.5(d),39.6
(d),38.3(t),38.0(d),34.5(t),33.5
(t),30.3(d),19.8(t),15.9(q) s:singlet,d:doublet,t:triplet, q:qultet 2 下記の理化学的性質を有し、分子式
C32H38O13で表される抗生物質SK−1071を生産
する能力を有するストレプトミセス属に属する微
生物を培地に好気的に培養し、該抗生物質SK−
1071を生産蓄積させ、これを採取することを特徴
とする抗生物質SK−1071の製造法。 比旋光度:〔α〕18 D−0.1゜(C=1、アセトニト
リル) 紫外線吸収スペクトル:λCH 3 CN naxnm(ε)277
(6170)、350(4660)に吸収帯を有する。 赤外線吸収スペクトル:3400,1760,1740,
1710,1640,1600cm-1に吸収帯を有する。 C−13核磁気共嗚スペクトル:重アセトン中
のケミカルシフト ppm172.3(s),157.5
(d),144.0(s),139.5(s),135.3(s),
131.6(d),125.7(d),123.4(d),98.4(d)

88.9(d),79.5(d),76.8(s),74.3(d),73
.6
(t),69.7(d),67.4(d),66.3(d),65.3
(t),61.0(q),59.6(q),46.5(d),39.6
(d),38.3(t),38.0(d),34.5(t),33.5
(t),30.3(d),19.8(t),15.9(q) s:singlet,d:doublet,t:triplet, e:qultet
[Claims] 1. Having the following physical and chemical properties and having a molecular formula of C 32 H 38 O 13
Antibiotic SK-1071 represented by. Specific optical rotation: [α] 18 D −0.1° (C=1, acetonitrile) Ultraviolet absorption spectrum: λ CH 3 CN nax nm (ε) 277
It has absorption bands at (6170) and 350 (4660). Infrared absorption spectrum: 3400, 1760, 1740,
It has absorption bands at 1710, 1640, and 1600 cm -1 . C-13 nuclear magnetic resonance spectrum: chemical shift in heavy acetone ppm 172.3 (s), 157.5
(d), 144.0 (s), 139.5 (s), 135.3 (s),
131.6(d), 125.7(d), 123.4(d), 98.4(d)

88.9(d), 79.5(d), 76.8(s), 74.3(d), 73
.6
(t), 69.7(d), 67.4(d), 66.3(d), 63.3
(t), 61.0 (q), 59.6 (q), 46.5 (d), 39.6
(d), 38.3 (t), 38.0 (d), 34.5 (t), 33.5
(t), 30.3 (d), 19.8 (t), 15.9 (q) s: singlet, d: doublet, t: triplet, q: qultet 2 Has the following physical and chemical properties and has a molecular formula
A microorganism belonging to the genus Streptomyces that has the ability to produce the antibiotic SK-1071 represented by C 32 H 38 O 13 is cultured aerobically in a medium, and the antibiotic SK-1071 is grown in a medium.
A method for producing antibiotic SK-1071, which comprises producing and accumulating 1071 and collecting it. Specific optical rotation: [α] 18 D −0.1° (C=1, acetonitrile) Ultraviolet absorption spectrum: λ CH 3 CN nax nm (ε) 277
It has absorption bands at (6170) and 350 (4660). Infrared absorption spectrum: 3400, 1760, 1740,
It has absorption bands at 1710, 1640, and 1600 cm -1 . C-13 nuclear magnetic resonance spectrum: chemical shift in heavy acetone ppm 172.3 (s), 157.5
(d), 144.0 (s), 139.5 (s), 135.3 (s),
131.6(d), 125.7(d), 123.4(d), 98.4(d)

88.9(d), 79.5(d), 76.8(s), 74.3(d), 73
.6
(t), 69.7(d), 67.4(d), 66.3(d), 65.3
(t), 61.0 (q), 59.6 (q), 46.5 (d), 39.6
(d), 38.3 (t), 38.0 (d), 34.5 (t), 33.5
(t), 30.3 (d), 19.8 (t), 15.9 (q) s: singlet, d: doublet, t: triplet, e: qultet
JP60108427A 1985-05-22 1985-05-22 Novel antibiotic substance sk-1071 and production thereof Granted JPS61268187A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60108427A JPS61268187A (en) 1985-05-22 1985-05-22 Novel antibiotic substance sk-1071 and production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60108427A JPS61268187A (en) 1985-05-22 1985-05-22 Novel antibiotic substance sk-1071 and production thereof

Publications (2)

Publication Number Publication Date
JPS61268187A JPS61268187A (en) 1986-11-27
JPH0468319B2 true JPH0468319B2 (en) 1992-11-02

Family

ID=14484493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60108427A Granted JPS61268187A (en) 1985-05-22 1985-05-22 Novel antibiotic substance sk-1071 and production thereof

Country Status (1)

Country Link
JP (1) JPS61268187A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106918612A (en) * 2017-02-23 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe nano-probes

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106950240A (en) * 2017-02-23 2017-07-14 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on ZnSe nano-probes
CN106918611A (en) * 2017-02-23 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeZr nano-probes
CN106950239A (en) * 2017-02-23 2017-07-14 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on ZnS nano-probes
CN107044989A (en) * 2017-02-23 2017-08-15 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Ni nano-probes
CN107014847A (en) * 2017-02-23 2017-08-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on NiPt nano-probes
CN106918613A (en) * 2017-02-23 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeZrO nano-probes
CN107014848A (en) * 2017-03-11 2017-08-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeRh nano-probes
CN107037067A (en) * 2017-03-22 2017-08-11 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Co nano-probes
CN107044990A (en) * 2017-03-22 2017-08-15 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on CdTe nano-probes
CN107037068A (en) * 2017-03-22 2017-08-11 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on CoZr nano-probes
CN107037069A (en) * 2017-03-22 2017-08-11 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on CoPt nano-probes
CN107044991A (en) * 2017-03-30 2017-08-15 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on CoFeB nano-probes
CN106918614A (en) * 2017-03-30 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on AlSb nano-probes
CN106918615A (en) * 2017-03-30 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on AlP nano-probes
CN107064200A (en) * 2017-03-31 2017-08-18 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeSi nano-probes
CN106918616A (en) * 2017-03-31 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe Co nano-probes
CN107014851A (en) * 2017-03-31 2017-08-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeZrB nano-probes
CN107014852A (en) * 2017-04-10 2017-08-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeSiCo nano-probes
CN106932428A (en) * 2017-04-10 2017-07-07 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on TiO2 nano-probes
CN107085004A (en) * 2017-04-10 2017-08-22 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Ni Gd C nanos probe
CN106996943A (en) * 2017-04-10 2017-08-01 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on NdFeB nano-probes
CN107179331A (en) * 2017-04-10 2017-09-19 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe Si Nb Cu nano-probes
CN107144590A (en) * 2017-04-10 2017-09-08 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe Ta Cu B nano-probes
CN106970104A (en) * 2017-04-10 2017-07-21 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe Zr Cu B nano-probes
CN107144589A (en) * 2017-04-10 2017-09-08 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe Co Ni nano-probes
CN106932427A (en) * 2017-04-10 2017-07-07 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on FeAlO nano-probes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106918612A (en) * 2017-02-23 2017-07-04 南昌大学 A kind of method that anaerobic bacteria Inhibitors form Chinese Traditional Medicinal Herbs are screened based on Fe nano-probes

Also Published As

Publication number Publication date
JPS61268187A (en) 1986-11-27

Similar Documents

Publication Publication Date Title
JPH0468319B2 (en)
CA1174622A (en) Enzyme inhibitor produced by cultivation of streptomyces microorganisms
US4107297A (en) Antibiotic compound
CA1277623C (en) Enkephalinase b inhibitors, their preparation, and pharmaceutical compositions containing the same
CA1209935A (en) Biologically active ws 6049 substances, a process for the production thereof and their pharmaceutical compositions
TSUNAKAWA et al. Quartromicin, a Complex of Novel Antiviral Antibiotics I. Production, Isolation, Physico-Chemical Properties and Antiviral Activity
JP4521145B2 (en) Antibiotic caprazomycin and its production
US4423218A (en) Antibiotic neplanocin A
CA1165710A (en) Antibiotic oxanosine and a process for the production thereof
Komiyama et al. Louisianins A, B, C and D: Non-steroidal growth inhibitors of testosterone-responsive SC 115 cells I. Taxonomy, fermentation, isolation and biological characteristics
CA2012074A1 (en) Ws7622a, b, c and d substances, derivatives thereof, processes for preparation thereof and use thereof
JPS5823077B2 (en) Antibiotic AM-3603 and its manufacturing method
JP3530563B2 (en) KO-8119 substance and process for producing the same
JP2971204B2 (en) New substance WK-2955 and method for producing the same
JPH0448793B2 (en)
JPS632266B2 (en)
EP0236948A2 (en) Novel compounds WK-142 and process for preparing the same
JP2868237B2 (en) Novel bioactive substance OM-6519 and production method thereof
JPH0365347B2 (en)
JP2573018B2 (en) Antibiotic WK-1875 and method for producing the same
JPH0372237B2 (en)
JPH0631311B2 (en) Antibiotics RK-1061A, RK-1061B, and RK-1061C and method for producing the same
JPS62186787A (en) Novel microorganism
JPS62205055A (en) Novel physiologically active substance sk-1894 and production thereof
JPS6366155A (en) Novel antibiotic jietacins and manufacture

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees